Press Releases

Date Title  
Toggle Summary Audentes Therapeutics Appoints Stephen Squinto, Ph.d. To Its Board Of Directors
SAN FRANCISCO, CA – April 21, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced the appointment of Stephen Squinto, Ph.D., to the company’s Board of
Toggle Summary Audentes Therapeutics Joins Global Organizations In Celebrating Rare Disease Day® 2015
New Audentes Patient Advocacy Website Created to Serve Patient Community SAN FRANCISCO, CA – February 26, 2015 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced
Toggle Summary Audentes Therapeutics Raises $42.5 Million In Series B Financing
Deerfield, Sofinnova, and Venrock Join Existing Investors to Propel Leading Gene Therapy Company Through Significant Clinical and Corporate Development Milestones SAN FRANCISCO, CA – December 2, 2014 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and
Toggle Summary Audentes Therapeutics To Present At The Piper Jaffray Healthcare Conference
SAN FRANCISCO, CA – November 20, 2014 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced that Matthew Patterson, President and Chief Executive Officer, will
Toggle Summary Audentes Therapeutics Announces Continued Expansion Of Senior Management Team
John T. Gray, Ph.D., Brings Leading Gene Therapy Research and Manufacturing Expertise to Company SAN FRANCISCO, CA – October 1, 2014 – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene therapy products for patients with serious, rare
Toggle Summary Audentes Therapeutics To Present At The Leerink Partners Rare Disease Roundtable
SAN FRANCISCO, CA – September 24, 2014 – Audentes Therapeutics, Inc., a private biotechnology company dedicated to the development and commercialization of gene therapy products for patients with serious, rare diseases, today announced that Matthew Patterson, President and Chief Executive Officer,
Toggle Summary Audentes Therapeutics Announces Six Abstracts To Be Presented At The American Society Of Gene And Cell Therapy Meeting May 21-24, 2014
Data to be presented demonstrate continued encouraging results from preclinical studies of AT001 for the treatment of X-Linked Myotubular Myopathy SAN FRANCISCO – May 19, 2014   – Audentes Therapeutics, Inc., a biotechnology company committed to the development and commercialization of gene
Toggle Summary Audentes Therapeutics Announces Significant Additions To Leadership Team
Dr. Suyash Prasad joins as Senior Vice President and Chief Medical Officer SAN FRANCISCO, CA – March 4, 2014   – Audentes Therapeutics, Inc., a biotechnology company dedicated to the development and commercialization of innovative treatments for rare diseases using gene therapy technology, has
Toggle Summary Audentes Therapeutics And Genethon Announce Agreement To Develop Treatment For Severe Genetic Disease X-linked Myotubular Myopathy
Promising preclinical data recently published in Science Translational Medicine SAN FRANCISCO, CA – February 5, 2014 – Audentes Therapeutics, Inc., a biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, and Genethon, a non-profit organization
Toggle Summary REGENX BIOSCIENCES AND AUDENTES THERAPEUTICS ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DEVELOPMENT OF TREATMENTS FOR SERIOUS, RARE MUSCLE DISEASES USING NAV™ VECTORS
WASHINGTON & SAN FRANCISCO – July 30, 2013 – REGENX Biosciences, LLC and Audentes Therapeutics, Inc. announce that they have entered into an agreement for the development and commercialization of products to treat X-Linked Myotubular Myopathy (XLMTM) and Pompe disease